



Graeme Boocock PhD

Patent Agent, Partner

T 613.369.4775
F 613.230.8842
Ottawa
GBoocock@blg.com
[LinkedIn](#)

[Intellectual Property](#)
[Patents](#)
[Health Care & Life Sciences](#)
[Health Law](#)

Graeme holds a PhD in medical and molecular genetics and has postdoctoral research experience in protein engineering. He drafts and prosecutes patent applications in the life sciences, with particular expertise in antibody-related technologies, gene editing, diagnostics and personalized medicine. Graeme also assists clients with Plant Breeders' Rights (PBR) applications and is himself an amateur breeder of *Passiflora* varieties.

Graeme conducted his doctoral research at The Hospital for Sick Children (University of Toronto), which culminated in the discovery of the human gene that is mutated in Shwachman-Diamond syndrome - an inherited disease involving bone marrow failure, leukemia risk, pancreatic exocrine insufficiency and varied developmental problems. Graeme then worked for three years as a postdoctoral researcher at the MRC Laboratory of Molecular Biology in Cambridge, U.K., focusing on synthetic biology and protein engineering.

Experience

- Drafting and prosecuting patent applications for biotechnology, life sciences and pharmaceutical inventions for Canadian and international patent offices.
- Providing opinions on patentability, infringement, validity and freedom-to-operate issues.
- Advising and assisting with technology transfer in Canadian universities and teaching hospitals.

Insights & Events

- Author, "Guide to Plant Breeders' Rights in Canada", BLG Article, November 2018
- Author, "Excess claims fees vs. double patenting in Canadian prosecution", BLG Article, June 2024
- Author, "Legislative provisions delineating double patenting would be beneficial for all", BLG Article, June 2024
- Author, "Update on forthcoming patent term adjustment in Canada", BLG Article, May 2024
- Author, "NGT Plants: Patent Eligibility and Protection in Canada", BLG Article, March 2024
- Author, "Canada's new excess claims fees vs double patenting", BLG Article, June 2023
- Author, "Patent term adjustment is coming to Canada", BLG Article, April 2023
- Author, "Navigating new excess claims fees and double patenting risk in Canadian patent prosecution: The devil and the deep blue sea", BLG Article, September 2022
- Author, "Significant changes coming to the Canadian patent system", BLG Article, June 2022
- Author, "Changes to Canadian patent examination: delayed and still uncertain", BLG Article, January 2022
- Author, "Patenting antibodies in Canada? Don't forget claims to competitive antibodies", BLG Article, September 2021
- Author, "CIPO releases revised guidelines for subject matter eligibility", BLG Article, November 2020
- Author, "Federal Court of Canada corrects CIPO on claims construction", BLG Article, August 2020
- Speaker, "Antibody and Epitope/Competitive Binding Claims: A Canadian Perspective," AIPPI World Congress 2019 (London), Sept. 16, 2019
- Author, "Judicial Exclusions to Patent Eligibility in the U.S. – The Beginning of the End?", BLG Article, July 2019
- Author, "Significant changes are on the horizon for Canadian patent prosecution", BLG Article, July 2019
- Co-Author: [Antibody Patenting: A Practitioner's Guide to Drafting, Prosecution and Enforcement, August 2019](#)
- Author, "Beware the election you didn't make", BLG Article, December 2018
- Author, "CIPO's Examination Guidelines for Medical Diagnostic Methods Turn Three", BLG Article, July 2018
- Speaker, "Canada's Cha(lle)nging Patent Landscape," Chartered Institute of Patent Attorneys (CIPA) Scotland Meeting (Glasgow), May 18, 2018
- Author, "CIPO-EPO Patent Prosecution Highway Pilot Agreement Extended with Revised Eligibility Criteria", BLG Article, January 2018
- Co-author, "Canada's Diagnostic Examination Practice Faces Scrutiny," LifeSigns: Life Sciences Legal Trends in Canada, 2018
- Speaker, "Patents, Policy, and Precision Medicine: Challenges to Bringing" Innovative Products to Market," Healthy Canada Conference: Access to Affordable Medicines (The Conference Board of Canada), April 26-27, 2017
- Author, "Canadian Patent Appeal Board Upholds Claims to Non-Exemplified Humanized Antibodies", BLG Article, August 2016
- Author, "Haunted by the Spirit of the Invention: Recent Examination Guidelines from the Canadian Intellectual Property Office for Medical Diagnostics Channel the Spectre of Contribution Analysis," The Canadian Intellectual Property Review, January 2016

Beyond Our Walls

Professional Involvement

- Member, Intellectual Property Institute of Canada

- Member, International Association for the Protection of Intellectual Property (AIPPI)

Awards & Recognitions

- Recognized in the 2024 and previous editions of *Intellectual Asset Magazine's (IAM) Patent 1000 - The World's Leading Patent Professionals* (Prosecution - Recommended).

Bar Admission & Education

- Registered Canadian Patent Agent, 2014
- Registered U.S. Patent Agent for Canadian applicants, 2014
- PhD (medical and molecular genetics), University of Toronto, 2006
- BSc (Hons) (molecular genetics and molecular biology), University of Toronto, 1999

BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[blg.com](https://www.blg.com)

© 2024 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.